细胞毒性T细胞
表位
抗原处理
CTL公司*
免疫学
主要组织相容性复合体
免疫系统
MHC I级
抗原
与抗原处理相关的转运体
抗原呈递
生物
CD8型
过继性细胞移植
病毒学
T细胞
遗传学
体外
作者
Thorbald van Hall,Elisabeth Z. Wolpert,Peter A. van Veelen,Sandra Laban,Michael van der Veer,Marjet Roseboom,Sandra A. Bres,Per Grufman,Arnoud de Ru,Hugo D. Meiring,Ad de Jong,Kees L. M. C. Franken,Antoinette Teixeira,Rob Valentijn,Jan W. Drijfhout,Frits Koning,Marcel Camps,Ferry Ossendorp,Klas Kärre,Hans‐Gustaf Ljunggren
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2006-03-19
卷期号:12 (4): 417-424
被引量:153
摘要
Defects in major histocompatibility complex (MHC) class I-restricted antigen presentation are frequently observed in human cancers and result in escape of tumors from cytotoxic T lymphocyte (CTL) immune surveillance in mice. Here, we show the existence of a unique category of CTLs that can prevent this escape. The CTLs target an alternative repertoire of peptide epitopes that emerge in MHC class I at the surface of cells with impaired function of transporter associated with antigen processing (TAP), tapasin or the proteasome. These peptides, although derived from self antigens such as the commonly expressed Lass5 protein (also known as Trh4), are not presented by normal cells. This explains why they act as immunogenic neoantigens. The newly discovered epitopes can be exploited for immune intervention against processing-deficient tumors through adoptive T-cell transfer or peptide vaccination.
科研通智能强力驱动
Strongly Powered by AbleSci AI